The bioavailability and blood levels of low-dose rapamycin for longevity in real-world cohorts of normative aging individuals.

ABSTRACT: Rapamycin, also known as sirolimus, has demonstrated great potential for application in longevity medicine. However, the dynamics of low-dose rapamycin bioavailability, and any differences in bioavailability for different formulations (e.g., compounded or commercial), remain poorly understood. We thus explored rapamycin bioavailability in two real-world cohorts to begin providing a foundational understanding of differences in effects between formulations over time. The small trial study cohort was utilized to explore the blood rapamycin levels of commercial (n = 44, dosages 2, 3, 6, or 8 mg) or compounded (n = 23, dosages 5, 10, or 15 mg) rapamycin 24 h after dose self-administration. Results suggested dose-to-blood level relationships were linear for both formulations, though compounded h

SUBMITTER: Harinath G 

PROVIDER: S-EPMC12397450 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature